Literature DB >> 33489887

The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy.

Irina Filimonova1, Daniela Schmidt2, Sina Mansoorian1, Thomas Weissmann1, Hadi Siavooshhaghighi1, Alexander Cavallaro3, Torsten Kuwert2, Christoph Bert1, Benjamin Frey1, Luitpold Valentin Distel1, Sebastian Lettmaier1, Rainer Fietkau1, Florian Putz1.   

Abstract

BACKGROUND: Traditional clinical target volume (CTV) definition for pelvic radiotherapy in prostate cancer consists of large volumes being treated with homogeneous doses without fully utilizing information on the probability of microscopic involvement to guide target volume design and prescription dose distribution.
METHODS: We analyzed patterns of nodal involvement in 75 patients that received RT for pelvic and paraaortic lymph node metastases (LNs) from prostate cancer in regard to the new NRG-CTV recommendation. Non-rigid registration-based LN mapping and weighted three-dimensional kernel density estimation were used to visualize the average probability distribution for nodal metastases. As independent approach, the mean relative proportion of LNs observed for each level was determined manually and NRG and non-NRG levels were evaluated for frequency of involvement. Computer-automated distance measurements were used to compare LN distances in individual patients to the spatial proximity of nodal metastases at a cohort level.
RESULTS: 34.7% of patients had pelvic LNs outside NRG-consensus, of which perirectal was most common (25.3% of all patients) followed by left common iliac nodes near the left psoas major (6.7%). A substantial portion of patients (13.3%) had nodes at the posterior edge of the NRG obturator level. Observer-independent mapping consistently visualized high-probability hotspots outside NRG-consensus in the perirectal and left common iliac regions. Affected nodes in individual patients occurred in highly significantly closer proximity than at cohort-level (mean distance, 6.6 cm vs. 8.7 cm, p < 0.001).
CONCLUSIONS: Based on this analysis, the common iliac level should extend to the left psoas major and obturator levels should extend posteriorly 5 mm beyond the obturator internus. Incomplete coverage by the NRG-consensus was mostly because of perirectal involvement. We introduce three-dimensional kernel density estimation after non-rigid registration-based mapping for the analysis of recurrence data in radiotherapy. This technique provides an estimate of the underlying probability distribution of nodal involvement and may help in addressing institution- or subgroup-specific differences. Nodal metastases in individual patients occurred in highly significantly closer proximity than at a cohort-level, which supports that personalized target volumes could be reduced in size compared to a "one-size-fits-all" approach and is an important basis for further investigation into individualized field designs.
Copyright © 2021 Filimonova, Schmidt, Mansoorian, Weissmann, Siavooshhaghighi, Cavallaro, Kuwert, Bert, Frey, Distel, Lettmaier, Fietkau and Putz.

Entities:  

Keywords:  lymph node metastases; mapping; patterns of recurrence; pelvic radiotherapy; prostate cancer

Year:  2021        PMID: 33489887      PMCID: PMC7820617          DOI: 10.3389/fonc.2020.590722

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  29 in total

1.  3D Slicer as an image computing platform for the Quantitative Imaging Network.

Authors:  Andriy Fedorov; Reinhard Beichel; Jayashree Kalpathy-Cramer; Julien Finet; Jean-Christophe Fillion-Robin; Sonia Pujol; Christian Bauer; Dominique Jennings; Fiona Fennessy; Milan Sonka; John Buatti; Stephen Aylward; James V Miller; Steve Pieper; Ron Kikinis
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

2.  Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.

Authors:  Aurélie De Bruycker; Elise De Bleser; Karel Decaestecker; Valérie Fonteyne; Nicolaas Lumen; Pieter De Visschere; Kathia De Man; Louke Delrue; Bieke Lambert; Piet Ost
Journal:  Eur Urol       Date:  2018-11-29       Impact factor: 20.096

3.  Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients.

Authors:  Hanneke J M Meijer; Ansje S Fortuin; Emile N J T van Lin; Oscar A Debats; J Alfred Witjes; Johannes H A M Kaanders; Jelle O Barentsz
Journal:  Radiother Oncol       Date:  2012-11-27       Impact factor: 6.280

4.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Authors:  Jeremie Calais; Johannes Czernin; Minsong Cao; Amar U Kishan; John V Hegde; Narek Shaverdian; Kiri Sandler; Fang-I Chu; Chris R King; Michael L Steinberg; Isabel Rauscher; Nina-Sophie Schmidt-Hegemann; Thorsten Poeppel; Philipp Hetkamp; Francesco Ceci; Ken Herrmann; Wolfgang P Fendler; Matthias Eiber; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2017-11-09       Impact factor: 10.057

5.  High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy.

Authors:  Hanneke J M Meijer; Emile N van Lin; Oscar A Debats; J Alfred Witjes; Paul N Span; Johannes H A M Kaanders; Jelle O Barentsz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

6.  Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer.

Authors:  Daniel Walacides; Astrid Meier; Anne Caroline Knöchelmann; Daniele Meinecke; Thorsten Derlin; Frank M Bengel; Tobias L Ross; Hans-Jürgen Wester; Katja Derlin; Markus A Kuczyk; Christoph A J von Klot; Hans Christiansen; Christoph Henkenberens
Journal:  Strahlenther Onkol       Date:  2019-01-04       Impact factor: 3.621

7.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Authors:  M Roach; M DeSilvio; C Lawton; V Uhl; M Machtay; M J Seider; M Rotman; C Jones; S O Asbell; R K Valicenti; S Han; C R Thomas; W S Shipley
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

8.  RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.

Authors:  Colleen A F Lawton; Jeff Michalski; Issam El-Naqa; Mark K Buyyounouski; W Robert Lee; Cynthia Menard; Elizabeth O'Meara; Seth A Rosenthal; Mark Ritter; Michael Seider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-22       Impact factor: 7.038

9.  Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.

Authors:  Robert J Myerson; Michael C Garofalo; Issam El Naqa; Ross A Abrams; Aditya Apte; Walter R Bosch; Prajnan Das; Leonard L Gunderson; Theodore S Hong; J J John Kim; Christopher G Willett; Lisa A Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-29       Impact factor: 7.038

10.  PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

Authors:  A De Bruycker; A Spiessens; P Dirix; N Koutsouvelis; I Semac; N Liefhooghe; A Gomez-Iturriaga; W Everaerts; F Otte; A Papachristofilou; M Scorsetti; M Shelan; S Siva; F Ameye; M Guckenberger; R Heikkilä; P M Putora; A Zapatero; A Conde-Moreno; F Couñago; F Vanhoutte; E Goetghebeur; D Reynders; T Zilli; P Ost
Journal:  BMC Cancer       Date:  2020-05-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.